Coronary-artery bypass surgery in patients with left ventricular dysfunction.

Area of Science:

• Cardiology
• Cardiac Surgery
• Heart Failure Management

Background:

• The established role of coronary-artery bypass grafting (CABG) in treating patients with coronary artery disease (CAD) and heart failure (HF) remains unclear.
• Optimal treatment strategies for this patient population require further investigation.

Purpose of the Study:

• To evaluate the efficacy of CABG in addition to medical therapy for patients with CAD and heart failure.
• To compare the primary outcome of all-cause mortality between medical therapy alone and CABG plus medical therapy.

Main Methods:

• A randomized trial involving 1212 patients with ejection fraction ≤35% and CAD suitable for CABG.
• Patients were assigned to either medical therapy alone (602) or medical therapy plus CABG (610).
• Primary outcome: all-cause mortality. Secondary outcomes: cardiovascular death, and all-cause death or cardiovascular hospitalization.

Main Results:

• No significant difference in the primary outcome of all-cause mortality (41% vs. 36%, P=0.12).
• CABG group showed lower rates of cardiovascular death (28% vs. 33%, P=0.05) and composite of all-cause death or cardiovascular hospitalization (58% vs. 68%, P<0.001).
• High rates of CABG utilization in both groups during follow-up (91% in CABG group, 17% in medical therapy group).

Conclusions:

• CABG in addition to medical therapy did not significantly reduce all-cause mortality in patients with CAD and heart failure.
• CABG was associated with reduced rates of cardiovascular death and cardiovascular hospitalizations.
• The findings suggest a potential benefit of CABG for specific cardiovascular outcomes, warranting careful consideration in treatment decisions.